.

Notice: Trying to access array offset on value of type int in /home/customer/www/ryseam.com/public_html/templates/yoo_master2/warp/src/Warp/Config/Repository.php on line 243

Team

WE'RE A PASSIONATE UNIFIED FORCE WHO HAVE SUCCESSFULLY SCALED AND EXITED COMPANIES

RYSE creates value by supporting early-stage companies to scale their revenue and distribution. We work with exceptional founders to negotiate attractive contracts with our established distribution partners.



Kevin Roberts

Kevin Roberts CNZM, CEO-in-Residence

Kevin is an international business leader, founder, and educator, who has been a global CEO for over 30 years. As former CEO and Chairman at Saatchi & Saatchi Worldwide, one of the world’s leading creative organisations, he has built some of the most respected global brands.

Kevin started his career with iconic London fashion house Mary Quant and, at 32, became CEO of Pepsi-Cola Middle East and later in Canada, over-taking Coke in the ‘Cola Wars’. He coaches influential business leaders on leadership, marketing, and wrote Lovemarks: the Future Beyond Brands, a ground-breaking book published in 18 languages and named one of the ten Ideas of the decade in 2009. His latest best-selling book 64 Shots: Leadership in a Crazy World offers business leaders frameworks and solutions from his experience building global brands for Visa, Toyota, Walmart, Novartis, Boston Scientific, and J&J.

Kevin holds honorary professorial appointments at business schools globally – advising nations and global organisations across commerce, media, and sport. He is Resident Expert for Oxford University’s Foundry accelerator, former director of the legendary All Blacks New Zealand Rugby Football Union, Chairman of USA Rugby, CEO-In-Residence at Cambridge Judge Business School, and was made a Companion of the New Zealand Order of Merit (CNZM).

Interview Contact
Dr John Lee Allen

Dr John Lee Allen, Managing Partner

John is a founder and investor with a background as a physician and research scientist. He has driven innovation in Europe, United States, and Asia, raising millions in seed investment, expanding into new markets, and launching from Silicon Valley's renowned Y Combinator accelerator.

John is Expert-In-Residence at Imperial College London, a Fellow at the University of Cambridge, on the Digital Health Council at The Royal Society of Medicine, and NHS Board Governor at Cambridge University Hospitals. In 2012, he took a leading role in Specsavers' expansion into the hearing care market and was appointed a national NHS Clinical Entrepreneur Fellow & Mentor - the largest programme to validate healthcare technologies globally.

John holds degrees in Engineering, Medicine, and developed an implantable device as a Neuroscience PhD student at Oxford University. He has held R&D and innovation roles at Harvard University, Johns Hopkins, National University of Singapore, the World Health Organization, and has published across Science, Technology, and Medicine.

LinkedIn This email address is being protected from spambots. You need JavaScript enabled to view it.
Dr Laila Samady-Mustad

Dr Laila Samady-Mustad, Investment Committee

Laila is a scientist, advisor, entrepreneur and investor with more than 25 years’ experience in the pharmaceutical, medical and biotechnology industry in the UK, US and France. Her expertise is in medical affairs, partnerships, business development and capital raising strategies.

Based in London, she is also a Director at Pannexus, a consultancy firm specialising in business development, marketing and international trade opportunities within the sectors of retail and government. Previously, she held senior executive positions, scientific and business development roles, in several early-stage medical technology companies in the USA, Vigilent Labs, Covanos Inc., G3 Therapeutics. While at Boehringer Ingelheim, she served in increasingly senior roles in Washington DC and London, leading to Global Partnerships in Oncology.

Laila holds a PhD in Molecular Pathology and Immunology from University College London and her work led to a spin-out company, BioVex, which was acquired by Amgen for $1Bn.

LinkedIn This email address is being protected from spambots. You need JavaScript enabled to view it.
Dr David Holbrook

Dr David Holbrook, Investment Committee

David has a long track record as a leader in university technology spinouts and investment. As a qualified doctor, and after senior roles at Glaxo and Roche, he headed up Imperial’s spinout incubator, the medtech investing strategy at MTI, and Seed Fund at LifeArc.

David is a leader in the field of UK university technology spinouts and investment. As a qualified doctor, and after senior roles at Glaxo and Roche, he headed up Imperial’s spinout incubator, the medtech investing strategy at MTI, and Seed Fund at LifeArc (formerly Medical Research Council Technologies). He was an early advocate of the convergence of the technology and life sciences sectors, including investment in ApaTech – a bone graft company sold to Baxter for $300m. He is also a director of AIM-listed healthcare company Oxford BioDynamics and senior independent director at The Worldwide Healthcare Trust plc.

David holds degrees from the University of Oxford, King’s College London, and an MBA from Harvard Business School.

LinkedIn This email address is being protected from spambots. You need JavaScript enabled to view it.
Annalisa Jenkins

Dr Annalisa Jenkins, Chair

Annalisa is a healthcare leader building teams from scientific research through clinical development, regulatory approval, and into healthcare systems globally. She is a board member at the Milken Institute, Genomics England, and member of the Science Advisory Board at the FDA.

Annalisa is a healthcare thought leader with a 25-year track record in building teams from scientific research through clinical development, regulatory approval, and into healthcare systems globally. She served as CEO of Dimension Therapeutics, a gene therapy company that was acquired by Ultragenyx Pharmaceutical Inc., is Chair of the Court at the London School of Hygiene and Tropical Medicine, Trustee of the British Heart Foundation, Advisory Board member at MedCity, FasterCures, a Center of the Milken Institute, Genomics England, and member of the Science Advisory Board at the FDA.

Annalisa holds a degree in Medicine, specialised in Cardiovascular Medicine, served as a Medical Officer in the British Royal Navy, and prior leadership roles have included the head of global research and development at Merck Serono.

LinkedIn Contact
Eric Kostegan

Eric Kostegan, Impact Lead

Eric is US-based and has a track record leading impact and philanthropic healthcare ventures globally. Ventures have raised over $600m with organisations in healthcare including Mount Sinai Health System, Jefferson Health, and Mass General Brigham (Harvard).

Eric is an impact investing and venture philanthropy leader with a 25-year track record building and leading innovative healthcare programmes and ventures globally. He has raised over $600m in capital with specific expertise working with organisations in healthcare including Mount Sinai Health System, Jefferson Health, and Mass General Brigham (Harvard) Integrated Health Care System.

Eric is based between the east and west coast and is highly recognised for creating innovative, measurable, and metrics-focused programmes to engage stakeholders and foster collaboration across healthcare.

LinkedIn Contact
Chris Sawyer

Chris Sawyer, Venture Advisor

Chris is Digital Health Innovation Lead at Innovate UK - the UK's innovation agency has invested over £1.5 billion in innovation - supported 5,000+ innovative companies and added £7.5 billion to the UK economy.

Chris is Digital Health Innovation Lead at Innovate UK - the UK's innovation agency has invested over £1.5 billion in innovation, helped more than 5,000 innovative companies, added £7.5 billion to the UK economy, and created 35,000 extra new jobs. He has over 30 years’ experience in the healthcare technology sector, supported innovative technological solutions for NHS Innovation Hubs, and was an Associate Director of Innovation for an NHS organisation.

Chris has extensive international and domestic product management experience with market leading medical device manufacturers including Phillips and Hewlett-Packard.

LinkedIn Contact
Dr Benjamin Maddison

Dr Benjamin Maddison, Venture Advisor

Ben is a PhD scientist with a passion for creating tomorrow through scalable sustainable innovation and business transformation with some of the largest global consumer brands for Costa Coffee and Unilever.

Ben’s passion is creating tomorrow through scalable sustainable innovation and business transformation. His background in commercial innovation, strategy, change and project management uniquely positions him with a blend of valuable skills, knowledge and broad sector experience. This is with some of the largest global companies including Costa Coffee, owned by The Coca-Cola Company, and leading consumer healthcare brands at Unilever. His 18+ years experience spans several industries including healthcare, pharmaceutical, public sector and consumer goods.

Ben holds a PhD from Imperial College London, specialising in molecular neurochemistry, an undergraduate degree in Biochemistry, and has a proven track record on launching disruptive innovations in global markets.

LinkedIn Contact
Dr Andreas Hadjinicolaou

Dr Andreas Hadjinicolaou, Venture Analyst

Andreas is a Cambridge and Oxford universities clinician-scientist specialised in immunotherapy and early cancer diagnostics.

Andreas is a clinician-scientist, specialising in gastroenterology, with academic interests in oncology and immunology with particular focus on early cancer diagnostics and immunotherapy. His research work has led to numerous peer-reviewed publications, prizes, two patent applications, and collaborations with pharmaceutical and biotech companies. He has been a research scholar at Stanford University, held investigator roles in several clinical studies and worked with NICE-NHS Evidence, and the BSG Artificial Intelligence Task Force.

Andreas holds degrees from the Universities of Cambridge (BA, MD) and Oxford (MA, PhD) with distinctions and multiple prestigious awards for academic excellence.

LinkedIn Contact
Heejung Koo

Dr Heejung Koo, Venture Analyst

Heejung is a systems biologist with 7 years of expertise in the AI drug discovery sector and is currently pursuing her MBA at London Business School.

Heejung is a systems biologist with 7 years of expertise in the AI drug discovery sector and is currently pursuing her MBA at London Business School. Before MBA, she contributed to Standigm, South Korea's pioneering AI drug discovery company, where she spearheaded the development of an AI platform for therapeutic target identification. Relocating to Cambridge, UK, she established Standigm's inaugural international subsidiary and served as VP of Strategic Alliances. Here, she facilitated fruitful collaborations between UK and European enterprises and the company's Korean headquarters.

Heejung holds a Ph.D. in Interdisciplinary Bioscience and Bioengineering from Pohang University of Science and Technology, South Korea.

LinkedIn Contact
Chris Turner

Chris Turner, Entrepreneur in Residence

Chris is a serial entrepreneur and founder of a digital health start-up acquired by Co-op Health. He is a qualified pharmacist and national NHS Clinical Entrepreneur Fellow and Mentor.

Chris is a serial entrepreneur and the founder of Dimec, the UK based digital healthcare start-up that was acquired by Co-op Health in 2018. Dimec, now Co-op Health, facilitates the ordering of repeat prescriptions by linking patients directly with their GP surgery. It was the very first GP and pharmacy integrated service, giving patients the choice of collecting their prescriptions from any high street pharmacy in England or having them delivered.

Chris holds a first class Master in Pharmacy degree, is an NHS qualified pharmacist, and an NHS Clinical Entrepreneur Fellow.

LinkedIn Contact
Shabir Chowdhary

Shabir Chowdhary, Managing Partner

Shabir is a founder and investor with a background in banking - Merrill Lynch, Morgan Stanley, and Schroders - who has scaled companies across multiple sectors. These companies have raised in excess of $4.5bn and have sold to strategic buyers globally.

Shabir has a track record of scaling companies and supporting company founders across multiple sectors. The majority of his career has been spent building and managing asset management companies across Europe. He was successful in developing and executing fundraising and marketing strategies that enabled collaboration with private groups and public bodies and substantial investment from a variety of highly reputable foundations, endowments, charities, pension funds, insurance companies as well as fund of funds and bank investors.

Shabir holds a BSc (Hons) in Biochemistry and an MBA from Imperial College London. On leaving university, he spent several years in banking with Merrill Lynch, Morgan Stanley, and Schroders. Asset management businesses Shabir has been involved with have raised in excess of $4.5bn in aggregate and sold to several strategic buyers.

LinkedIn This email address is being protected from spambots. You need JavaScript enabled to view it.
Vivien de Tusch-Lec

Vivien de Tusch-Lec, General Partner

Vivien is a serial technology founder - with 3 exits - and investor with a background as a journalist graduating from Cambridge University and INSEAD. She ran the Tech, Media, Telecom unit for B2B Marketplace Gerson Lehman Group.

Vivien has a track record as an investor, entrepreneur, and has had 3 exits as a start-up founder (Infinancials, Bubele, Martialfunk). She ran the Tech, Media, Telecom unit for B2B Marketplace Gerson Lehman Group - and has been supporting the Investment Committee at RYSE. In 2018, she was a co-investor during the first investment programme with DigitalHealth.London and MedCity, in Skin Analytics and LiveSmart, and now manages a portfolio of technology investments.

Vivien loves operating in start-ups, is an advisor to Loyal VC, a former journalist, and non-exec director at Techspert.io. She holds a Master's degree from the University of Cambridge and an MBA from INSEAD.

LinkedIn This email address is being protected from spambots. You need JavaScript enabled to view it.
David Seemungal

David Seemungal, Distribution Lead

David has over 25 years’ experience in healthcare investment, policy, and distribution – as Head of Pharmaceutical & Biotechnology Equity Research at ING’s investment banking division, Deputy Head at S&P Global, and Senior Policy Advisor at the Wellcome Trust.

At the Wellcome Trust, he led the horizon scanning team to identify and analyse commercial research opportunities ahead of significant investment. David is Director at healthcare consultancy Synopia, and previously Director at Cubase Consulting and Global Business Development Director at SastoMed GmbH, a German wound care company. His focus has been assessing the competitive landscape for new products and identifying commercial distribution partners for pharma, biotech, and medtech companies.

David has a first-class degree in Microbiology & Genetics from Cardiff University, and three years postgraduate research experience at Imperial College London.

LinkedIn This email address is being protected from spambots. You need JavaScript enabled to view it.
Everett Kamin

Everett Kamin, Board Advisor

Everett has VC, Private Equity and Investment Banking experience across 30 countries. 100+ direct investment transactions totalling in excess of $50B. 25+ years in Healthcare, Tech, Logistics, and Staffing, whilst holding private and public company board level seats.

Everett has VC, Private Equity and Investment Banking experience across 30 countries. 100+ direct investment transactions totalling in excess of $50B. 25+ years in Healthcare, Tech, Logistics, and Staffing, whilst holding private and public company board level seats.

Everett holds an MBA from University of Warwick - Warwick Business School, Fintech from Wharton Executive Education, and BSBA Finance & Accounting from Questrom School of Business, Boston University.

LinkedIn This email address is being protected from spambots. You need JavaScript enabled to view it.
Fergus Hay

Fergus Hay, Board Advisor

Fergus is a technology and media leader with a track record in commercial transformation, product innovation and growth. He sat on the annual fundraising committee of the British Heart Foundation and is a regular commentator on global tech news for Sky, NBC, and the BBC.

Fergus is a technology and media leader with a track record in commercial transformation, product innovation and growth, with experience in North America, Asia, and Europe. He is the CEO and founder of marketing advisory firm Elysian Fields specialising in venture backed tech companies, is Non-Exec Chairman of digital healthcare company Vida Care, and sat on the annual fundraising committee of the biggest funder of UK cardiovascular research (British Heart Foundation). Previously he was CEO of marketing agency Leagas Delaney climbing the ranks for growth to #3 in the UK, and held various executive roles at Ogilvy & Mather in North America and Asia.

Fergus holds a combined MBA from LSE, HEC Paris, NYU Stern and is a regular commentator on global tech news for Sky, NBC, and the BBC.

LinkedIn Contact
John Pennant

John Pennant, Partnership Lead

John is US-based and has a 20-year track record generating £100+ million in philanthropic and partnership funding across King’s College London, King’s Health Partners, University of Cambridge, and major healthcare institutions in the United States.

He was formerly Senior Principal Gift Fundraiser at King’s College London and King’s Health Partners from 2017-2022, where he actively raised millions from recognised groups in the UK and internationally. Funding included support for COVID-19 response and research, Children and Young People’s Mental Health, Chair in Addictions, Evelina London Nursing Scholarships, Autism research, Air Quality Research, Child Health Lecturer as well as working with a team to secure an 8-figure investment in King’s Business School’s Qatar Centre for Global Banking and Finance.

John also held senior roles at the University of York, the University of British Columbia and Churchill College, Cambridge.

LinkedIn Contact
Dr Aleksandar Petrovic

Dr Aleksandar Petrović, Venture Advisor

Aleksandar is a healthcare leader with expertise in life sciences industry spanning strategy consulting (IQVIA), entrepreneurial market expansion (Sensirion) and digital innovation (Siemens).

Aleksandar is a healthcare leader with expertise in life sciences industry spanning strategy consulting (IQVIA), entrepreneurial market expansion (Sensirion) and digital innovation (Siemens). With a background in clinical neurology and engineering, he defined, developed and commercialised novel medical devices and diagnostics. These include Research and Development to launch of a brain perfusion MR imaging solution as well as development of a disruptive go-to-market strategy for a $1B insulin pump business.

Aleksandar holds a doctorate from the University of Oxford, a US Department of State leadership award, is a certified negotiator in difficult negotiations (Schranner Negotiation Institute) and has held research and innovation positions at Harvard University and Massachusetts General Hospital.

LinkedIn Contact
Dr Vishaal Virani

Dr Vishaal Virani, Venture Advisor

Vishaal is Head of YouTube Health at Google UK. He is co-founder of Doctorpreneurs - the world’s largest community of medical innovators - and worked with leading global healthcare brands at Reckitt Benckiser.

Vishaal is a medical doctor, strategy consultant, and co-founder of Doctorpreneurs - the world’s largest community of medical innovators – with skills across digital health, private equity due diligence and corporate strategy. He has worked on the leading global consumer healthcare brands at Reckitt Benckiser (RB), business development at digital healthcare company Ada Health, and is currently working on health partnerships at YouTube.

Vishaal holds degrees in Medicine and in International Health from University College London. He is Governor of the Royal Free NHS Trust, Mentor at DigitalHealth.London, and guest lecturer at London Business School.

LinkedIn Contact
Dr Alexander Azizi

Dr Alexander Azizi, Venture Analyst

Alexander is a Cambridge University academic doctor specialising in innovation in therapeutics and oncology.

Alexander is an academic doctor specialising in pharmacology, therapeutics, and medical oncology. He is based between the University of Cambridge and CRUK Cambridge Institute. He has won multiple academic awards including from the National Institute for Health Research, The University of Cambridge and the European Society for Medical Oncology. His current laboratory grant focuses on immunogenomics and current translational work is in collaboration with an international biopharmaceutical group focusing on cancer combination therapies.

In addition to his work in venture capital, he works as a technical consultant across Europe and Asia for a large technology incubator.

LinkedIn Contact
Dr Louise Glanvill

Dr Louise Glanvill, Venture Analyst

Louise is a Physician and Plastic & Reconstructive Surgeon that has made significant strides in healthcare innovation and transformation following her MBA at London Business School.

Louise Glanvill, MD MBA, is a Plastic & Reconstructive Surgeon, making significant strides in healthcare innovation and transformation following her MBA at London Business School. Louise has excelled in healthcare venture capital investment, showcasing her expertise by sourcing and conducting due diligence. Her dedication to healthcare extends beyond investment; her experience in surgery with the NHS and an Anatomy Demonstrator at the University of Oxford underscores her commitment to frontline healthcare delivery and education.

Louise's academic foundation in Neuroscience (MA) from the University of Oxford and Medicine (MBBS) from Imperial College London, combined with her leadership roles in various healthcare societies and committees, highlights her dedication to advancing healthcare through strategic investment, innovation, and a deep understanding of medical sciences.

LinkedIn Contact

Joomla! Debug Console

Session

Profile Information

Memory Usage

Database Queries